Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT)

This is Archived Content. This content is available for historical purposes only. It may not reflect the current state of science or language from the National Institute on Drug Abuse (NIDA). View current information on nida.nih.gov.

This study will assess the comparative effectiveness of extended release injectable naltrexone (XR-NTX) versus buprenorphine-naloxone (BUP-NX) as pharmacotherapeutic aids to recovery amongst treatment-seeking heroin- and/or prescription opioid-dependent participants.  The primary goal of the study is to estimate the difference, if one exists, between XR-NTX and BUP-NX in the distribution of the time to relapse during the 6-month trial.

CTN Protocol ID: 
CTN-0051
ClinicalTrials.gov ID: 

Principal Investigator(s)

John Rotrosen, M.D.
Professor
NYU School of Medicine
Department of Psychiatry
One Park Avenue, 8th Floor
New York, NY 10016
john.rotrosen@nyumc.org